Priovant Therapeutics, Inc.

Alumis, Inc. planned to raise between $282.4m and $317.7m in the last biopharmaceutical initial public offering in the US during the first half of 2024, but instead grossed $250m on 27 June from the

Roivant Sciences Ltd. said it is poised to take on AbbVie Inc. ’s Humira in non-infectious uveitis, a leading cause of blindness, after reporting Phase II data showing that brepocitinib met its prim

Roivant Sciences Ltd. and its subsidiary Priovant Therapeutics still have big plans for the dual TYK2/JAK1 inhibitor brepocitinib, but those plans no longer include further development in systemic

Ventyx Biosciences, Inc. provided a disappointing update to shareholders on 6 November, revealing that despite meeting primary and secondary endpoints in a Phase II trial in plaque psoriasis, it is e